(Q54077157)

24 May 2018

title

Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma. (English)

1 reference

24 May 2018

6

Buzdar AU

1 reference

24 May 2018

author name string

Ibrahim NK

1

1 reference

24 May 2018

Rahman Z

2

1 reference

24 May 2018

Valero V

3

1 reference

24 May 2018

Willey J

4

1 reference

24 May 2018

Theriault RL

5

1 reference

24 May 2018

Murray JL 3rd

7

1 reference

24 May 2018

Bast R

8

1 reference

24 May 2018

Hortobagyi GN

9

1 reference

24 May 2018

language of work or name

English

0 references

publication date

1 October 1999

1 reference

24 May 2018

published in

Cancer

1 reference

24 May 2018

volume

86

1 reference

24 May 2018

issue

7

1 reference

24 May 2018

page(s)

1251-1257

1 reference

24 May 2018

Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion

cites work

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819991001%2986%3A7%3C1251%3A%3AAID-CNCR21%3E3.0.CO%3B2-F

Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819991001%2986%3A7%3C1251%3A%3AAID-CNCR21%3E3.0.CO%3B2-F

Taxol: a novel investigational antimicrotubule agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819991001%2986%3A7%3C1251%3A%3AAID-CNCR21%3E3.0.CO%3B2-F

A phase III study comparing the clinical utility of four regimens of 5-Fluorouracil.A preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819991001%2986%3A7%3C1251%3A%3AAID-CNCR21%3E3.0.CO%3B2-F

Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819991001%2986%3A7%3C1251%3A%3AAID-CNCR21%3E3.0.CO%3B2-F

A randomized phase I and II study of short-term infusion of high-dose fluorouracil with or without N-(phosphonacetyl)-L-aspartic acid in patients with advanced pancreatic and colorectal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819991001%2986%3A7%3C1251%3A%3AAID-CNCR21%3E3.0.CO%3B2-F

Five-day continuous-infusion vinblastine in the treatment of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819991001%2986%3A7%3C1251%3A%3AAID-CNCR21%3E3.0.CO%3B2-F

Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819991001%2986%3A7%3C1251%3A%3AAID-CNCR21%3E3.0.CO%3B2-F

Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819991001%2986%3A7%3C1251%3A%3AAID-CNCR21%3E3.0.CO%3B2-F

Clinical pharmacology of 5-fluorouracil

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819991001%2986%3A7%3C1251%3A%3AAID-CNCR21%3E3.0.CO%3B2-F

Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819991001%2986%3A7%3C1251%3A%3AAID-CNCR21%3E3.0.CO%3B2-F

5-Fluorouracil rechallenge by protracted infusion in refractory breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819991001%2986%3A7%3C1251%3A%3AAID-CNCR21%3E3.0.CO%3B2-F

21 January 2018

Vinorelbine: an overview

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819991001%2986%3A7%3C1251%3A%3AAID-CNCR21%3E3.0.CO%3B2-F

A model for the action of vinblastine in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819991001%2986%3A7%3C1251%3A%3AAID-CNCR21%3E3.0.CO%3B2-F

Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819991001%2986%3A7%3C1251%3A%3AAID-CNCR21%3E3.0.CO%3B2-F

Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819991001%2986%3A7%3C1251%3A%3AAID-CNCR21%3E3.0.CO%3B2-F

Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819991001%2986%3A7%3C1251%3A%3AAID-CNCR21%3E3.0.CO%3B2-F

Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819991001%2986%3A7%3C1251%3A%3AAID-CNCR21%3E3.0.CO%3B2-F

Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819991001%2986%3A7%3C1251%3A%3AAID-CNCR21%3E3.0.CO%3B2-F

Phase I study of protracted venous infusion of 5-fluorouracil

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819991001%2986%3A7%3C1251%3A%3AAID-CNCR21%3E3.0.CO%3B2-F

Phase I/II trial of continuous infusion vinorelbine for advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819991001%2986%3A7%3C1251%3A%3AAID-CNCR21%3E3.0.CO%3B2-F

Vinorelbine as first-line chemotherapy for metastatic breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819991001%2986%3A7%3C1251%3A%3AAID-CNCR21%3E3.0.CO%3B2-F

10.1002/(SICI)1097-0142(19991001)86:7<1251::AID-CNCR21>3.0.CO;2-F

21 January 2018

Identifiers

DOI

1 reference

24 May 2018

1 reference

24 May 2018